1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Treatment used at scanning for each study groupa
MedicationCSSC (No.)Software-Assisted (No.)
Fingolimod35.85% (19)37.30% (282)
Natalizumab32.08% (17)27.12% (205)
Dimethyl fumarate3.77% (2)7.80% (59)
Alemtuzumab1.89% (1)3.44% (26)
Glatiramer acetate5.66% (3)2.78% (21)
Interferon β5.66% (3)3.57% (27)
Otherb9.43% (5)6.61% (50)
No active treatment5.66% (3)11.38% (86)
Total100% (53)100% (756)
Proportion on higher efficacy therapies (fingolimod/natalizumab/alemtuzumab)69.87%67.84%
  • ↵a This table summarizes the number and proportion for each disease-modifying agent at scanning.
  • ↵b Other treatments include teriflunomide, ocrelizumab, rituximab, stem cell transplantation.